Blackbaud (BLKB) Q1 2026 Earnings Transcript

Blackbaud reported Q1 organic revenue growth of 4.2% to $281 million, adjusted EBITDA of $99 million, and non-GAAP EPS up 20% to $1.14, with free cash flow improving to $37 million from a negative prior-period result. Management reiterated 2026-2030 targets for 4%-6% organic revenue growth, 6%-8% adjusted EBITDA growth, and 13%+ non-GAAP EPS CAGR, while also expanding share repurchase plans and launching its first agentic AI product into general availability. The main near-term caution is that adjusted EBITDA dollars are expected to decline slightly year over year in Q2 due to planned AI investments.

Analysis

Blackbaud is becoming a higher-quality compounder, but the market is likely underestimating how much of the next leg is coming from mix shift rather than headline growth. The key inflection is that AI is not just a margin story; it is a distribution wedge that expands spend into fundraising budgets, which should support both attach rates and pricing power without forcing a seat-based model that would invite procurement pushback. That makes the product more resilient than a generic AI add-on, because the buyer is tied to mission outcomes and donor productivity, not software usage alone.

The second-order effect is that agentic AI could actually deepen moat economics before it becomes a meaningful standalone revenue line. If the new product creates workflow lock-in inside the system of record, then renewal duration and cross-sell should improve while CAC falls, especially in verticals with limited IT resources. The enterprise win suggests the sales motion is broadening upward in deal size, which matters more than unit volume because it validates Blackbaud as a platform vendor rather than a point solution.

The near-term risk is quarter-to-quarter optics: management is explicitly pulling EBITDA dollars lower in Q2 to fund AI, and that can invite a multiple de-rating if investors focus on the wrong quarter. But the bigger risk/reward hinge is adoption velocity over the next two to three quarters; if the agent starts converting webinar interest into multi-year contracts, consensus EPS revisions could move materially higher because buybacks amplify even modest operating upside. Conversely, if AI monetization remains early and spend ramps faster than conversion, the stock could stagnate despite solid fundamentals.

Contrarian view: the market may be too focused on the AI narrative and not enough on the underlying capital return engine. With meaningful buybacks already shrinking the share count, BLKB can deliver double-digit EPS growth even in a middling revenue environment, which creates downside support that is not fully visible in the top line. That combination makes the stock less of a pure AI call and more of a self-funding compounding story with optional upside if the agent category scales.

Key Decisions for Investors

• Long BLKB on a 6-12 month horizon; entry is attractive on any post-earnings pullback driven by Q2 margin optics. Risk/reward is favorable if the market overreacts to temporary AI spend while ignoring buybacks and long-duration contracts.
• Buy BLKB call spreads 3-6 months out to express upside from agent monetization and EPS revisions without paying for full equity beta. Best if you expect adoption headlines and guidance confidence to re-rate the multiple before year-end.
• Pair trade: long BLKB / short a lower-quality horizontal SaaS peer with weaker buyback support and no clear distribution wedge. The thesis is that BLKB should outperform on downside capture because cash returns and contract duration cushion the multiple.
• If already long BLKB, hold through Q2 but hedge with a small short-dated put spread into the quarter to protect against the expected EBITDA dip. The risk is a narrative-driven de-rate if investors fixate on investment spend rather than forward monetization.
• Add on confirmation only if the next two quarters show conversion of agent interest into signed multi-year subscriptions; that is the key catalyst for a sustainable upward revision cycle.